Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Revamps Neuroscience R&D – New Site, New Mandate, New Leadership

Executive Summary

Pfizer has thoroughly revamped its approach to neuroscience R&D, emphasizing disease biology and neural circuitry, moving its research team from Groton, Conn. to Cambridge, Mass., and hiring an eminent neuroscientist to lead the group.

You may also be interested in...



Pfizer’s Geno Germano Talks M&A Strategy

The big pharma is evaluating a full spectrum of M&A opportunities, Pfizer Global Innovative Pharma Business President Germano said in an interview. Whether that includes another bid for AstraZeneca remains to be seen, but when it comes to a potential tax inversion deal, he said business is business.

Out Of The Wilderness: A Second Chance For Neuropsychiatric R&D?

The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.

Lieber Institute Fills Gap In Neuropsychiatric Research Ecosystem, Seeks Pharma Partnerships

At a time of resurgent interest in CNS, The Lieber Institute for Brain Development’s capabilities and tissue resources set it apart from other brain research initiatives. The privately backed research lab is focused on translating genetic clues to the cause and course of schizophrenia and related disorders into new treatments.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel